Mr. Speaker, I have three petitions to table.
The first petition I am tabling states that brain cancer, in 2023, affected 3,200 Canadians and claimed the lives of 2,500. Vorasidenib is a life-extending medication currently only available in the United States. It remains inaccessible to Canadians. The petitioners are calling on the Government of Canada to improve access to brain cancer treatments by empowering Health Canada to expedite the use of patient and laboratory in vitro data to expand access to drugs for brain cancer treatment where clinical trials are not feasible and develop a regulatory model that would permit the approval of brain cancer treatment medications that can extend patients' lives.
The second petition is with respect to pulmonary arterial hypertension, which is a rare, life-threatening condition. Recent results from the STELLAR clinical trials offer new hope for patients, and the petitioners are calling on the Government of Canada to urge Health Canada to approve sotatercept, a significant milestone in the treatment option for PAH, without further delay.
The third petition is on the same topic of pulmonary arterial hypertension. The petition talks about patients needing timely access to new therapies. Therefore, the petitioners are calling on the federal government to allocate funding now to the provinces so that new treatments can be made available quickly to Canadians living with this rare disease and that the federal government have a holistic approach to rare diseases that includes early detection and prevention, timely and equitable access to evidence-based care, enhanced community support, and the promotion of innovative research.